News
Mandatory Notification of Trade
19.11.2007 - Cleverling Business, a company controlled by Daniel Laroque - president of MIG and board member
of Nutri Pharma, has transferred a total of 200.000 shares...
Update - Meridian International Group (MIG)
10.12.2007 - As previously reported, MIG has obtained a significant reduced cost structure,
including an improved B/E turnover....
Improved tax assessment
14.11.2007 - In our stock exchange release of 14 February 2007 we informed that Nutri Pharma had received a draft proposal from the tax authorities regarding change of the company`s tax assessments for the income years 2001-2003...
Read more about Improved tax assessmentMandatory Notification of Trade
23.11.2007 - Cleverling Business, a company controlled by Daniel Laroque -president of MIG and board member of Nutri Pharma, has transferreda total of 800.000 shares in Nutri Pharma....
Read more about Mandatory Notification of TradeNew IT supplier in MIG, reduced operating cost
12.11.2007 - An agreement has today been signed between Meridian International Group (MIG), wholly owned
subsidiary of Nutri Pharma ASA, Cleverling, controlled by the president of MIG and board
member in Nutri Pharma ASA, Daniel Laroque, and the former IT supplier Nexus, Meridian Art and
related parties...
Ekstraordinær Generalforsamling
06.11.2007 - Styret innkaller med dette til ekstraordinær generalforsamling i Nutri Pharma ASA tirsdag 20.
november kl. 13 i selskapets lokaler i Kronprinsesse Märthas Plass 1...
Mandatory Notification of Trade
24.08.2007 - Epsilon Eiendom AS, a company fully owned and controlled by CFO Lars H Enger and closely related family, has today purchased400.000 NUT shares at NOK 3,2094 per share....
Read more about Mandatory Notification of TradeMandatory Notification of Trade
24.08.2007 - Project manager Hilde Aalling Syvertsen has today purchased 500.000 NUT shares at NOK 3,20 per share from Lars Høie, board member of Nutri Pharma ASA....
Read more about Mandatory Notification of TradeSecond Quarter 2007
23.08.2007 - Nutri Pharma today reports revenues of MNOK 19.0 million and a loss of MNOK 0.8 million for the
second quarter of 2007...
Nutrifemme marketing and sales team
02.08.2007 - NutriFemme launch in Russia. The restructuring of the Russian operation is now showing results with record high orders booked in July.
Read more about Nutrifemme marketing and sales teamNutri Pharma launch of Nutrifemme in Russia
11.07.2007 - Nutri Pharma`s new female-health product will be launched as `NutriFemme` to the wholly-owned MIG direct marketing network at the annual `Premium` event in Moscow in August...
Read more about Nutri Pharma launch of Nutrifemme in RussiaMandatory notification of trade
25.04.07 - New board member in Nutri Pharma ASA Kristin Vestgren Sæterøy has today
purchased 500.000 NUT shares at NOK 2,74 per share from Lars Høie,
Board member of Nutri Pharma ASA...
First quarter 2007
24.05.2007 - Nutri Pharma (OSE: NUT) today reports revenues of MNOK 13, 5 million and a loss of MNOK 5,9 million for the first quarter of 2007. This compares to revenues of MNOK 22,6 and a loss of MNOK 3,2 million in the first quarter of 2006...
Read more about First quarter 2007New marketing director
02.05.2007 - Nutri Pharma ASA has employed Käthe Eva Bleken as marketing director.
As the main task, Käthe will be in charge of the launch and commercialization of NUT`s female
health products, which treats symptoms related to menopause and PMS (pre-menstrual symptoms)....
Mottatt firmaattest
27.04.2007 - Oslo Børs har mottatt firmaattest fra Nutri Pharma ASA i forbindelse med forhøyelse av aksjekapitalen. Se børsmelding 19.04.2007....
Read more about Mottatt firmaattestMeldepliktig handel
20.04.2007 - Styremedlem i Nutri Pharma, Kristin Vestgren Sæterøy, har i dag 20.04.07 kjøpt 5.000 aksjer i
Nutri Pharma til kurs 3,23....
Primary insider purchase of shares
19.04.2007 - Reference is made to the press release dated 19 April 2007 regarding the successfully completed
private placement in Nutri Pharma ASA....
Primary insider purchase of shares
19.04.2007 - Reference is made to the press release dated 19 April 2007 regarding the successfully
completed private placement in Nutri Pharma ASA...
Successfully completed private placement
19.04.2007 - Nutri Pharma ASA has on 18 April, 2007 successfully completed the private placement of a total of 7,865,000 new shares at a subscription price of NOK 3.10 per share.....
Read more about Successfully completed private placementPlanned private placement
18.04.2007 - Nutri Pharma ASA has retained Orion Securities ASA to advise on and execute a private placement of new shares directed towards professional Norwegian and international investors....
Read more about Planned private placementAnnual general meeting
18.04.2007 - General Meeting in Nutri Pharma ASA was held Wednesday 18 April 2007 at 10.00 hrs. All
items were resolved unanimously in accordance with the Boards Calling Notice...
Profit warning
13.04.2007 - Based on preliminary reporting the revenues from the CIS region are expected to come in around 30% lower in Q1 2007 compared to Q4 2006.
Read more about Profit warningNotice of Annual General meeting
The Annual general Meeting of Nutri Pharma ASA will be held Wednesday 18 April 2007, 10:00 a.m. at Hotel Continental, Stortingsgt. 24-26, 2 floor.
Read more about Notice of Annual General meetingApproval of proposed annual accounts
29.03.2007 - The Board of Directors of Nutri Pharma ASA has in a board meeting 29.03.2007 approved the final and audited accounts for 2006.The final results have not changed since the release of the preliminary accounts for 2006....
Read more about Approval of proposed annual accountsEU legislation opens new markets for Nutri Pharma
07.03.2007 - New EU legislation will enable companies who register a health claim made on food in one EU country to market this food using the same health claim in any EU member state. Nutri Pharma has awaited this legislation as it provides opportunities for companies who have made considerable investments in developing patented products with proven health benefits.
Read more about EU legislation opens new markets for Nutri PharmaMandatory notification of trade
05.03.2007 - Lars H. Enger, ny CFO i Nutri Pharma ASA fra 1/5-07 har kjøpt 45.000 aksjer i NUT til NOK 3,35 per
aksje. Beholding etter kjøp: Epsilon Eiendom AS: 500.000 aksjer og Lars H Enger: 200.000 aksjer.
Mandatory notification of trade
28.02.2007 - Epsilon Eiendom AS, a company fully owned and controlled by Lars H Enger and closely related
family, newly appointed CFO in Nutri Pharma ASA, has today purchased 500.000 NUT shares at NOK
2,88 per share from Lars Høie, Board member of Nutri Pharma ASA.
Fourth quarter and preliminary 2006 results
27.02.2007 - Nutri Pharma today reports total revenue for 2006 of MNOK 82.8 compared to MNOK 25.3 in 2005. The loss in 2006 is MNOK 11.3 (MNOK -10.5 in 2005) after amortisation charges of MNOK 9.1. The EBITDA loss in 2006 is MNOK 2.9 compared to a loss of MNOK 7.2 in 2005. Net financial revenue in 2006 is MNOK 0.7 compared to MNOK 0.1 last year.
Read more about Fourth quarter and preliminary 2006 resultsMandatory notification of trade
21.02.2007 - Punto, a company fully owned and controlled by Haakon Ambjørndalen, advisor to Nutri Pharma ASA, has today sold 232.000 NUT shares ...
Read more about Mandatory notification of tradeTax assessment
14.02.2007 - Nutri Pharma ASA has received a draft proposal from the tax authorities regarding change of the company`s tax assessments for the income years 2001-2003....
Read more about Tax assessmentMandatory notification of trade
06.02.2007 - Punto, a company fully owned and controlled by Haakon Ambjørndalen, advisor to Nutri Pharma ASA, has today sold 300.000 NUT shares at NOK 2,31 per share to Lars Høie, Board member of Nutri Pharma ASA.
Read more about Mandatory notification of tradeAmendment of terms regarding acquisition of MIG
05.02.2007 - Reference is made to previous communication regarding Nutri Pharma's acquisition of MIG and the terms therein. The purchase consideration of 24 million NUT shares to be paid for the MIG shares that were transferred to Nutri Pharma ASA on 1 July 2005 is regulated in the Share transfer agreement dated 1. June 2005 and Addendum 1 dated 12 September 2005.
Read more about Amendment of terms regarding acquisition of MIGNutri Pharma research on the detrimental effects of UHT processing of Soy protein published
17.01.2007 - A recently published placebo-controlled, randomised, double-blind clinical study over 4 weeks (80 persons) carried out in conjunction with the Karolinska Institute in Stockholm and the University of Potsdam in Berlin has found that soy protein products which have been UHT treated lose their ability to reduce serum cholesterol, and can significantly increase the levels of harmful LDL cholesterol.
Read more about Nutri Pharma research on the detrimental effects of UHT processing of Soy protein published